caa a22 4500 47574277X CHVBK 20180406123504.0 cr unu---uuuuu 170329e20000801xx s 000 0 eng 10.1007/s002400000110 doi (NATIONALLICENCE)springer-10.1007/s002400000110 Epithelial mucin expression in bladder cancer: correlation with pathological and clinical parameters [Elektronische Daten] [K. N. Syrigos, D. M. Deonarain, A. Karayiannakis, J. Waxman, T. Krausz, M. Pignatelli] Recently, attention has been drawn to the role of polymorphic epithelial mucin (PEM) as a possible target for cancer immunotherapy. To investigate the expression of this molecule in bladder tissue, we used two mouse monoclonal antibodies (HMFG1 and HMFG2) raised against the core protein of the PEM. The localization of these two anti-PEM antibodies was examined in normal (n=10), inflammatory (n=10) and malignant (n=67) bladder tissue samples with the use of a three-step avidin-biotin method. For HMFG1 and HMFG2 localization was successful in 78% and 60% of the bladder cancer samples, respectively, where as they were localized only in 30% and 40% of normal bladder tissue samples, respectively. Staining of either antibodies did not correlate with the grade, stage, or survival of bladder cancer patients. We conclude that PEM is frequently overexpressed by bladder cancer cells and HMFG1 is the antibody of choice to be used as a carrier of a cytotoxic agent for application of intravesical targeted therapy of bladder cancer. Springer-Verlag Berlin Heidelberg, 2000 Keywords Bladder cancer nationallicence MUC1 nationallicence Polymorphic epithelial mucin (PEM) nationallicence HMFG1 nationallicence HMFG2 nationallicence Immunotherapy nationallicence Syrigos K. N. Kifisias 40 & Arkadias, 115 26 Athens, Greece e-mail: knsyrigos@usa.net Tel.: +30-1-7719975; Fax: +30-1-7778838, GR aut Deonarain D. M. Department of Clinical Oncology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut Karayiannakis A. Department of Histopathology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut Waxman J. Department of Clinical Oncology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut Krausz T. Department of Histopathology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut Pignatelli M. Department of Histopathology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut https://doi.org/10.1007/s002400000110 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002400000110 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Syrigos K. N. Kifisias 40 & Arkadias, 115 26 Athens, Greece e-mail: knsyrigos@usa.net Tel.: +30-1-7719975; Fax: +30-1-7778838, GR aut NATIONALLICENCE 700 1- Deonarain D. M. Department of Clinical Oncology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut NATIONALLICENCE 700 1- Karayiannakis A. Department of Histopathology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut NATIONALLICENCE 700 1- Waxman J. Department of Clinical Oncology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut NATIONALLICENCE 700 1- Krausz T. Department of Histopathology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut NATIONALLICENCE 700 1- Pignatelli M. Department of Histopathology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, UK, GB aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer